{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=45", "query": { "condition": "Lung Cancer", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1138, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=44&page_size=10" }, "source": "local", "last_synced_at": "2026-10-15T10:57:21.452Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04789681", "title": "Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-07-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-14T06:28:20.524Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04789681" }, { "nct_id": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Dedifferentiated Liposarcoma", "Gastric / Gastroesophageal Junction Adenocarcinoma", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "HNSCC", "Leiomyosarcoma", "Leiomyosarcoma (LMS)", "Myxofibrosarcoma (MFS)", "NSCLC", "Non Small Cell Lung Cancer", "Sarcoma", "Solid Tumours", "Solitary Fibrous Tumors", "Undifferentiated Pleomorphic Sarcoma (UPS)" ], "interventions": [ { "name": "Fasting", "type": "OTHER" }, { "name": "Fed", "type": "OTHER" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" }, { "name": "OKN4395", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "OTHER", "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Epkin", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2025-01-23", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-14T22:46:51.353Z", "location_count": 3, "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789172" }, { "nct_id": "NCT05361174", "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage III Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Unresectable Melanoma" ], "interventions": [ { "name": "IOV-4001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 53, "start_date": "2022-07-20", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-03T00:01:48.084Z", "location_count": 11, "location_summary": "Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05361174" }, { "nct_id": "NCT05283330", "title": "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Cervical Cancer", "Colon Cancer", "Glioblastoma", "NSCLC", "Nonsmall Cell Lung Cancer", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "²¹²Pb-DOTAM-GRPR1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orano Med Theranostics, SAS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-12-22", "completion_date": "2032-05", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-14T19:42:25.577Z", "location_count": 8, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Glen Burnie", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283330" }, { "nct_id": "NCT05076760", "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Cutaneous Squamous Cell Carcinoma", "Head and Neck Cancer", "Melanoma", "Merkel Cell Carcinoma", "Metastatic Cancer", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Solid Tumor", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "MEM-288 Intratumoral Injection", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memgen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-04-21", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-15T10:57:21.452Z", "location_count": 2, "location_summary": "Tampa, Florida • Durham, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05076760" }, { "nct_id": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Primary Malignant Central Nervous System Neoplasm", "Locally Advanced Sarcoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Primary Malignant Central Nervous System Neoplasm", "Metastatic Sarcoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Avapritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-17T20:42:14.711Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771520" }, { "nct_id": "NCT07517198", "title": "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Hepatic Cancer", "High Grade Neuroendocrine Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Prostate Cancer", "Renal Carcinoma (Clear and Non-clear Cell)", "Small Cell Carcinomas of Non-lung Origin", "Small Cell Lung Cancer (SCLC)", "Solid Tumor", "Triple-negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "EXS74539", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-13", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-13T20:53:39.440Z", "location_count": 3, "location_summary": "Los Angeles, California • Fort Worth, Texas • West Valley City, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07517198" }, { "nct_id": "NCT05419076", "title": "A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases", "Brain Metastases, Adult", "Lung Cancer", "Lung Cancer Metastatic", "Small Cell Lung Carcinoma", "Small-cell Lung Cancer" ], "interventions": [ { "name": "Cerebrospinal fluid collection", "type": "PROCEDURE" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2022-06-10", "completion_date": "2027-06-10", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-08-01T23:27:36.853Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419076" }, { "nct_id": "NCT04332367", "title": "Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2020-08-01", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-08-02T08:14:18.912Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332367" }, { "nct_id": "NCT07636200", "title": "The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Solid Tumor Cancer", "Glioblastoma", "Small Cell Lung Cancer Extensive Stage", "Stage III Ovarian Cancer", "Stage IV Cancer (Solid Tumors Only)" ], "interventions": [ { "name": "Usual Care Control Condition", "type": "BEHAVIORAL" }, { "name": "Written Exposure-Based Coping Intervention (EASE)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Boulder", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2026-05-04", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-08-02T03:42:31.896Z", "location_count": 2, "location_summary": "Aurora, Colorado • Boulder, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07636200" } ] }